HeartBeam Inc. BEAT Archives

TuesdayJul 14, 2026 9:00 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Patent Expands Cardiac Monitoring Platform With Heart Failure and Structural Heart Disease Capabilities

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has received a new U.S. patent covering the integration of acoustic sensing and thoracic impedance measurement into its credit card-sized, cable-free ECG device. The expanded capabilities are designed to support future applications in structural heart disease and heart failure monitoring by enabling the device to function as a digital stethoscope and assess fluid accumulation in the chest without changing its existing form factor. The patent strengthens HeartBeam's intellectual property portfolio by adding capabilities that could enable earlier detection of heart valve abnormalities and fluid congestion in heart failure…

TuesdayJun 30, 2026 9:30 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Completes Enrollment Ahead of Schedule in Heart Attack Detection Pilot Study

HeartBeam (NASDAQ: BEAT) announced it has completed patient enrollment ahead of schedule in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The study enrolled 120 patients presenting with chest pain at two clinical sites in Belgrade, Serbia, with participants evaluated using both a standard 12-lead ECG and the company's 3D ECG technology. Data analysis is underway, and HeartBeam plans to present the results at a major cardiology conference later this year. The company said the study results are expected to support discussions with the FDA on the design of a planned U.S. pivotal trial and a…

MondayJun 22, 2026 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Launches Study Focused on Testing Proprietary Patch Capable of Generating On-Demand 12-Lead ECG for Ischemia Detection

The seriousness of coronary artery disease continues to intensify as populations age and cardiovascular risk factors become more common. HeartBeam announced the launch of a pilot study focused on evaluating its on-demand 12-lead ECG patch in detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, or ischemia. The study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (“MCT”) markets. Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of…

TuesdayJun 02, 2026 9:00 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Study Shows Portable ECG Device Can Help Identify Heart Attack Risk

HeartBeam (NASDAQ: BEAT) a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. HeartBeam said the proof-of-concept study evaluated 184 patients and found that the algorithm achieved an “area under the curve” (“AUC”) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms, rising to 92.9% when a personal, symptom-free baseline ECG was available for comparison. The company…

FridayMay 22, 2026 3:53 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Aims to Close Critical Gap in Early Cardiac Detection

HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising clinical need and evolving innovation. “One of the most persistent challenges in cardiac care is pre-hospital delay, with many patients not seeking medical attention at the onset of symptoms. Traditional electrocardiogram testing is typically conducted in clinical environments, which may not coincide with the onset of symptoms such as intermittent chest pain, palpitations or other warning signs. As a result, patients often defer care and clinicians are left without the data needed to make timely, informed decisions,”…

ThursdayMay 14, 2026 9:10 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Advances Commercial Launch, Reports First-Quarter 2026 Results

HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of its initial commercial partnerships in key U.S. markets, progress in its heart attack detection and ambulatory ECG patch initiatives, and an April public offering that raised $11.5 million in gross proceeds. The company reported a first-quarter net loss of $4.7 million, improved from $5.5 million in the prior-year period, with research and development expenses declining year over year as HeartBeam continued advancing commercialization of its FDA-cleared cardiac monitoring platform and related growth initiatives. To view the full press release, visit https://ibn.fm/guMCF About HeartBeam, Inc. HeartBeam,…

TuesdayMay 05, 2026 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Tackles Heart Disease with Next-Generation ECG Solutions

Cardiovascular disease remains the leading cause of death in the United States. One of the most persistent challenges in cardiac care is patient delay in seeking care. HeartBeam is working to address this gap by transforming how ECG data are collected and used through its HeartBeam System. Cardiovascular disease continues to be a major global health challenge, driven by aging populations, lifestyle factors and persistent gaps in early detection that continue to challenge healthcare systems. In response to these trends, HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at…

ThursdayApr 30, 2026 9:20 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q1 2026 Earnings Call and Provide Strategic Updates

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results ended March 31, 2026, and provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection and AI programs. To view the full press release, visit https://ibn.fm/yN939 About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting…

ThursdayApr 23, 2026 12:27 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Collaborates to Advance Next-Gen ECG Solutions

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed its collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology. The publication indicates that the move, “highlights HeartBeam’s growing focus on artificial intelligence (‘AI’)-enabled analysis and reinforces the relevance of its technology as healthcare increasingly shifts toward data-driven, remote monitoring solutions. The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate high value, AI-based ECG algorithms that can be deployed broadly across HeartBeam’s platform. These AI models may include patient-relevant wellness insights, condition-focused assessments, and applications for chronic condition management.” To view the…

FridayApr 17, 2026 9:10 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Closes $10 Million Public Offering to Advance Cardiac Technology Commercialization

HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering, supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors, will fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes To view the full press release, visit https://ibn.fm/9iNYY About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the…

Site Search

Company Search

Tag: HeartBeam Inc. BEAT